These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 20406858

  • 1. Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice.
    Abraham AK, Kagan L, Kumar S, Mager DE.
    J Pharmacol Exp Ther; 2010 Jul; 334(1):327-32. PubMed ID: 20406858
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.
    Marathe A, Van Wart S, Mager DE.
    J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):223-35. PubMed ID: 21165681
    [Abstract] [Full Text] [Related]

  • 4. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).
    Woo S, Krzyzanski W, Jusko WJ.
    J Pharmacokinet Pharmacodyn; 2007 Dec; 34(6):849-68. PubMed ID: 17943422
    [Abstract] [Full Text] [Related]

  • 5. Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.
    An G.
    J Clin Pharmacol; 2020 Feb; 60(2):149-163. PubMed ID: 31793004
    [Abstract] [Full Text] [Related]

  • 6. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice.
    McKenna SD, Vergilis K, Arulanandam AR, Weiser WY, Nabioullin R, Tepper MA.
    J Interferon Cytokine Res; 2004 Feb; 24(2):119-29. PubMed ID: 14980076
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens.
    Yan X, Ruixo JJP, Krzyzanski W.
    AAPS J; 2020 Jan 16; 22(2):30. PubMed ID: 31950308
    [Abstract] [Full Text] [Related]

  • 9. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
    Cao Y, Jusko WJ.
    J Pharmacokinet Pharmacodyn; 2014 Aug 16; 41(4):375-87. PubMed ID: 25077917
    [Abstract] [Full Text] [Related]

  • 10. Injury-induced type I IFN signaling regulates inflammatory responses in the central nervous system.
    Khorooshi R, Owens T.
    J Immunol; 2010 Jul 15; 185(2):1258-64. PubMed ID: 20562259
    [Abstract] [Full Text] [Related]

  • 11. Role of type I interferon signaling in human metapneumovirus pathogenesis and control of viral replication.
    Hastings AK, Erickson JJ, Schuster JE, Boyd KL, Tollefson SJ, Johnson M, Gilchuk P, Joyce S, Williams JV.
    J Virol; 2015 Apr 15; 89(8):4405-20. PubMed ID: 25653440
    [Abstract] [Full Text] [Related]

  • 12. A Full Target-Mediated Drug Disposition (TMDD) Model to Explain the Changes in Recombinant Human Erythropoietin (rhEpo) Pharmacokinetics in Patients with Different Bone Marrow Integrity Following Hematopoietic Transplantation.
    Wu N, Widness JA, Yan X, Veng-Pedersen P, An G.
    J Pharm Sci; 2022 Sep 15; 111(9):2620-2629. PubMed ID: 35691608
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers.
    Krzyzanski W, Wyska E.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun 15; 377(4-6):637-45. PubMed ID: 18071675
    [Abstract] [Full Text] [Related]

  • 14. Structure-function study of the extracellular domain of the human type I interferon receptor (IFNAR)-1 subunit.
    Kumaran J, Colamonici OR, Fish EN.
    J Interferon Cytokine Res; 2000 May 15; 20(5):479-85. PubMed ID: 10841076
    [Abstract] [Full Text] [Related]

  • 15. Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy Adults.
    Wu N, Katz DA, An G.
    Clin Pharmacokinet; 2023 Sep 15; 62(9):1275-1288. PubMed ID: 37452998
    [Abstract] [Full Text] [Related]

  • 16. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.
    Hensley SE, Cun AS, Giles-Davis W, Li Y, Xiang Z, Lasaro MO, Williams BR, Silverman RH, Ertl HC.
    Mol Ther; 2007 Feb 15; 15(2):393-403. PubMed ID: 17235319
    [Abstract] [Full Text] [Related]

  • 17. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
    Yan X, Mager DE, Krzyzanski W.
    J Pharmacokinet Pharmacodyn; 2010 Feb 15; 37(1):25-47. PubMed ID: 20012173
    [Abstract] [Full Text] [Related]

  • 18. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
    Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E.
    J Pharmacol Exp Ther; 2012 Jun 15; 341(3):702-8. PubMed ID: 22414855
    [Abstract] [Full Text] [Related]

  • 19. Neuronal Ablation of Alpha/Beta Interferon (IFN-α/β) Signaling Exacerbates Central Nervous System Viral Dissemination and Impairs IFN-γ Responsiveness in Microglia/Macrophages.
    Hwang M, Bergmann CC.
    J Virol; 2020 Sep 29; 94(20):. PubMed ID: 32796063
    [Abstract] [Full Text] [Related]

  • 20. MAVS-dependent IRF3/7 bypass of interferon β-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells.
    Takaki H, Honda K, Atarashi K, Kobayashi F, Ebihara T, Oshiumi H, Matsumoto M, Shingai M, Seya T.
    Mol Immunol; 2014 Feb 29; 57(2):100-10. PubMed ID: 24096085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.